CRBP
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.48
+3.03%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.31
From 52W high−61.36%
Volume1.15M
Market cap$144.67M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$7.31
From 52W high
−61.36%
Volume
1.15M
Market cap
$144.67M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
29.1
MomentumView details →
1D Return
+3.03%
YTD Return
−9.87%
SummaryUpdated Jun 1, 2026
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a biopharmaceutical company founded in 2009 and headquartered in Norwood, Massachusetts. The company went public in October 2014 and focuses on developing innovative immune modulators for treating immuno-oncology and fibrosis diseases. Corbus operates as a clinical-stage biotechnology company, meaning it is primarily engaged in research and development activities rather than commercial product sales, with multiple drug candidates in various stages of clinical trials.
Similar companies
Latest newsMore news →
Corbus Pharmaceuticals Holdings reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity treatment, with the drug avoiding depressive effects.6d agoCorbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $35.0 million for Q2 2026, with a net loss per share of $1.81.46d ago